Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Rest of the World Factor VIII Deficiency Treatment Market – A Significant Management for Hemophilia A Treatment

Novel product launches by the market players in the factor VIII deficiency treatment is expected to boost growth of the market over the forecast period. For instance, in June 2019, Novo Nordisk received marketing authorization from European commission for Esperoct in Europe. Esperoct is the brand name for turoctocog alfa pegol, N8-GP, indicated for surgical procedures in adolescents and adults with hemophilia A (congenital factor VIII deficiency). Moreover, in April 2019, Roche Products India Pvt Ltd launched hemophilia A drug emicizumab, branded as Hemlibra in India. It is indicated for prophylactic treatment for reducing frequency of bleeding episodes in patients with hemophilia A, through Factor VIII inhibitors.

Furthermore, increasing government initiatives to promote awareness about hemophilia treatment among population is expected to propel growth of the market over the forecast period. For instance, the National Bleeding Authority (NBA) provides funding to AHCDO (Australian Hemophilia Center Directors’ Organization) for treatment and management hemophilia A.  to support the effective management of hemophilia (Factor VIII Deficiency) in Australia.

The rest of the world factor VIII deficiency treatment market is expected to exhibit a CAGR of 4.7% over the forecast period (2019-2027).

Figure 1. Rest of the World Factor VIII Deficiency Treatment Market Value (US$ Mn), by Region, 2018

 | Coherent Market Insights

Rising cases of bleeding disorders is expected to boost growth of the rest of the world factor VIII deficiency treatment market

The rest of the world factor VIII deficiency treatment market is expected to witness significant growth, owing to rising cases of hemophilia or bleeding disorders. For instance, according to the Australian Bleeding Disorders Registry 2016 statistics, in 2015 there were around 4,941 patients, who suffered from common hereditary bleeding disorders, of which 2,301 patients were diagnosed with hemophilia A, and 548 patients were diagnosed with hemophilia B in Australia. Thus, increasing prevalence of hemophilia in Australia is expected to drive demand for factor VIII deficiency treatment over the forecast period. Moreover, increasing demand for efficient therapeutics for treatment of factor VIII deficiency from emerging economies such as India is expected to drive the market growth over the forecast period. For instance, according to the World Federation of Hemophilia, 2017 statistics, in India, around 18,353 people were diagnosed with hemophilia in 2016.

Figure 2. Rest of the World Factor VIII Deficiency Treatment Market Share (%), by Product Type, 2019 and 2027

 | Coherent Market Insights

Increasing healthcare expenditure and reimbursement policies in respective countries or regions are expected to drive the market growth

Latin America is expected to hold dominant position in the rest of the world factor VIII deficiency treatment market, owing to increasing per capita healthcare spending in Latin America, which is expected to drive the market growth in the region over the forecast period. For instance, according to the World Bank estimates, 2017, per capita healthcare expenditure increased significantly across Latin America during the six-year (2008-2014) interval, with an increase of 31% in Brazil, 54% in Chile, and 58% in Columbia.

Moreover, Asia Pacific is expected to be the second largest dominating region in the rest of the world factor VIII deficiency treatment market, owing to rising favorable reimbursement policies for hemophilia treatment in economies such as China, which is expected to drive the Asia Pacific market growth. For instance, according to the Chinese Ministry of Health report 2012, in China, outpatient hemophilia treatment is covered by health insurance schemes in over 80% of the cities in China, with reimbursement caps and patient co-pay requirements over 50%. Moreover, annual reimbursement is usually accounted below US$ 16,000.

Key Players

Major players operating in the rest of the world factor VIII deficiency treatment market include Baxter International, Inc., Biogen, Inc., Bayer AG, CSL Behring, Ferring B.V., F. Hoffmann-La Roche AG, Pfizer, Inc., Kedrion, and Novo Nordisk A/S.

Hemophilia, a factor VIII deficiency is a genetic disorder that is caused by the absence of factor VIII, which is a clotting protein. Moreover, it is genetically passed down to the offspring and according to the National Hemophilia Foundation, in 2019 about 1/3 cases of factor VIII deficiency occurs due to spontaneous mutation in the gene of the parents. Rising incidences and prevalence of hemophilic disorder are expected to boost growth of the market over the forecast period which leads to product launches in the market by the key players, to fulfill the unmet need of the market. Favorable regulatory scenarios and guidelines for the product launches and treatment are another leading factors that are expected to propel growth of the market over the forecast period.

Furthermore, adoption of inorganic strategies by market players such as collaborations to develop the novel therapies for the treatment is also expected to fuel growth of the factor VIII deficiency treatment market over the forecast period. For instance, in July 2019, Sangamo Therapeutics, Inc., a genomic medicine company, and Pfizer, Inc. announced updated results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A

Market Dynamics

Factor VIII deficiency treatment market is expected to witness significant growth over the forecast period, owing to increasing number of hemophilic cases. For instance, according to the World Federation of Hemophilia 2017 statistics, in India, around 18,353 people suffered from hemophilia and 15,218 people were diagnosed with hemophilia A in 2016, out of which around 83.0% had factor VIII deficiency.  Moreover, according to the World Federation of Hemophilia reports published in 2017, there were around 10,000 patients with hemophilia A in Brazil. With reference to prior data, World Federation of Hemophilia also reports that in 2017, Brazil had the third largest hemophilia patient population.  

Product approvals by the regulatory authorities is expected to drive the growth of factor VIII deficiency treatment market over the forecast period. For instance, in 2019 February, the U.S. Food and Drug Administration approved the biologics license application of Novo Nordisk’s long-acting recombinant factor VIII product, N8-GP Turoctocog alfa pegol (Esperoct), for prevention and treatment of individuals with hemophilia A. Moreover, in 2016 March, the U.S. Food and Drug Administration approved Kedrion’s, Koate Double Viral Inactivation (DVI) Antihemophilic Factor (human) with Mix2Vial, for the treatment of factor VIII deficiency.

Major players are also focused on adopting inorganic growth strategies such as acquisitions, which is expected to fuel the market growth over the forecast period. For instance, in 2018, CSL Behring acquired China-based plasma-derived therapies manufacturer, Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. from Humanwell Healthcare Group Co. Ltd. The acquisition has expanded CSL’s presence in China’s domestic plasma fractionation market. It has also enabled CSL to expand their commercial footprint and contributing their expertise for benefit of patients with rare diseases in China.

Key features of the study:

  • This report provides in-depth analysis of the factor VIII deficiency treatment market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2019 -2027), considering 2018 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the rest of the world factor VIII deficiency treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as part of this study include Baxter International, Inc., Biogen, Inc., Bayer AG, CSL Behring, Ferring B.V., F. Hoffmann-La Roche AG, Pfizer, Inc., Kedrion, and Novo Nordisk A/S
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding their future product launches, technology upgradation, market expansion, and marketing tactics
  • The global factor VIII deficiency treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the factor VIII deficiency treatment market.

Detailed Segmentation:

  • Rest of the World Factor VIII Deficiency Treatment Market, By Product Type:
    • Plasma Derived Coagulation Factor Concentrates
    • Recombinant Coagulation Factor Concentrates
    • Biologic (Hemlibra)
    • Desmopressin
  • Rest of the World Factor VIII Deficiency Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Rest of the World Factor VIII Deficiency Treatment Market, By Region:
    • Latin America
      • By Product Type:
        • Plasma Derived Coagulation Factor Concentrates
        • Recombinant Coagulation Factor Concentrates
        • Biologic (Hemlibra)
        • Desmopressin
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Colombia
        • Rest of Latin America
    • Asia Pacific
      • By Product Type:
        • Plasma Derived Coagulation Factor Concentrates
        • Recombinant Coagulation Factor Concentrates
        • Biologic (Hemlibra)
        • Desmopressin
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
          • Indonesia
          • Malaysia
          • Philippines
          • Singapore
          • Thailand
          • Rest of ASEAN Countries
        • Australia
        • South Korea
        • Pakistan
        • Rest of Asia Pacific
    • Middle East & Russia
      • By Product Type:
        • Plasma Derived Coagulation Factor Concentrates
        • Recombinant Coagulation Factor Concentrates
        • Biologic (Hemlibra)
        • Desmopressin
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
          • Saudi Arabia
          • United Arab Emirates
        • Israel
        • Russia
        • Turkey
        • Rest of Middle East
    • Africa
      • By Product Type:
        • Plasma Derived Coagulation Factor Concentrates
        • Recombinant Coagulation Factor Concentrates
        • Biologic (Hemlibra)
        • Desmopressin
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • North Africa
          • Algeria
          • Egypt
          • Tunisia
        • Central Africa
        • South Africa
  • Company Profiles
    • Baxter International, Inc*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Biogen, Inc.
    • Bayer AG
    • CSL Behring
    • Ferring B.V.
    • Hoffmann-La Roche AG
    • Pfizer, Inc.
    • Kedrion
    • Novo Nordisk A/S

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • New Therapy Developments
    • Epidemiology
    • Regulatory Scenario
    • Regulatory Guidelines
    • Reimbursement Scenario
    • PEST Analysis
    • Product Launch
    • PEST Analysis
  4. Rest of the World Factor VIII Deficiency Treatment Market, By Product Type, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Plasma Derived Coagulation Factor Concentrates
      • Introduction
      • Market Size, Volume and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million and Thousand Units)
    • Recombinant Coagulation Factor Concentrates
      • Introduction
      • Market Size, Volume and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million and Thousand Units)
    • Biologic (Hemlibra)
      • Introduction
      • Market Size, Volume and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million and Thousand Units)
    • Desmopressin
      • Introduction
      • Market Size, Volume and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million and Thousand Units)
  5. Rest of the World Factor VIII Deficiency Treatment Market, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Rest of the World Factor VIII Deficiency Treatment Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • Latin America
      • Market Size and Forecast, By Product Type, 2016 – 2027, ((US$ Million) and Volume (Thousand Units)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size (US$ Million), Volume (Thousand Units) and Forecast, and Y-o-Y Growth, By Country, 2016–2027)
        • Brazil
        • Mexico
        • Argentina
        • Colombia
        • Rest of Latin America
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million) and Volume (Thousand Units)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size (US$ Million), Volume (Thousand Units) and Forecast, and Y-o-Y Growth, By Country, 2016–2027)
        • China
        • India
        • Japan
        • ASEAN
          • Indonesia
          • Malaysia
          • Philippines
          • Singapore
          • Thailand
          • Rest of ASEAN Countries
        • Australia
        • South Korea
        • Pakistan
        • Rest of Asia Pacific
    • Middle East & Russia
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
          • Saudi Arabia
          • United Arab Emirates
        • Israel
        • Russia
        • Turkey
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million) and Volume (Thousand Units)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size (US$ Million), Volume (Thousand Units) and Forecast, and Y-o-Y Growth, By Country/Region, 2016–2027)
        • North Africa
          • Algeria
          • Egypt
          • Tunisia
        • Central Africa
        • South Africa
  7. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Baxter International, Inc.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Biogen, Inc.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Bayer AG
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • CSL Behring
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Ferring B.V.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • F. Hoffmann-La Roche AG
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Pfizer, Inc.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Kedrion
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Novo Nordisk A/S
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
    • Analyst Views
  8. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 40 market data tables and 25 figures on "Factor VIII Deficiency Treatment Market - Rest of the World forecast to 2027”.

Frequently Asked Questions

The rest of the world factor VIII deficiency treatment market is estimated to surpass US$ 3.06 billion by 2027.
The rest of the world factor VIII deficiency treatment market is estimated to exhibit a CAGR of 4.7% over the forecast period (2019-2027).
Major players operating in the rest of the world factor VIII deficiency treatment market include Baxter International, Inc., Biogen, Inc., Bayer AG, CSL Behring, Ferring B.V., F. Hoffmann-La Roche AG, Pfizer, Inc., Kedrion, and Novo Nordisk A/S.
Rising cases of bleeding disorders is one of the major factors that is expected to propel growth of the market over the forecast period.
Among product type, plasma derived coagulation factor concentrates segment held a dominant position in the rest of the world factor VIII deficiency treatment market in 2018.
Among regions, Latin America is expected to hold dominant position in the rest of the world factor VIII deficiency treatment market over the forecast period, followed by Asia Pacific.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner